Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxifluridine + mistletoe extract
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Doxifluridine is a second-generation fluoropyrimidine carbamate and a prodrug of 5-fluorouracil (5-FU). It is selectively converted to 5-FU by the enzyme thymidine phosphorylase, which is frequently overexpressed in tumor tissues, thereby disrupting DNA and RNA synthesis and inhibiting tumor growth. Mistletoe extract (Viscum album) is a botanical extract containing biologically active compounds such as mistletoe lectins (ML-I, II, and III) and viscotoxins. It is used as an adjuvant in oncology to modulate the immune system, induce apoptosis in cancer cells, and mitigate the side effects of chemotherapy. The combination of doxifluridine and mistletoe extract has been primarily investigated in East Asia, particularly South Korea, as a postoperative or palliative treatment for gastric cancer to enhance therapeutic efficacy and improve patient quality of life.
- Brand names
- FurtulonAbnoba-viscumIscadorHelixor
- Other names
- 5'-deoxy-5-fluorouridine + Viscum album extract5'-DFUR + mistletoe extract
02
Targets
Cell-surface galactose/N-acetyl-galactosamine-containing glycoconjugatesTS (Thymidylate synthase)
Beyond the preview
Go deeper on doxifluridine + mistletoe extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxifluridine + mistletoe extract.